RVL Pharmaceuticals PLC reports results for the quarter ended in September - Earnings Summary

RVL Pharmaceuticals

10/11/2022 23:33

* RVL Pharmaceuticals PLC  RVLP.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 16 cents per share.
    * Revenue rose 356.4% to $10.02 million from a year ago;
analysts
expected $10.22 million. 
    * RVL Pharmaceuticals PLC's reported EPS for the quarter was
a
loss of 16 cents​.
    * The mean earnings estimate of analysts had fallen by
about 3.9%
in the last three months.​ 
    * In the last 30 days two analysts negatively revised
earnings
estimates 
    * RVL Pharmaceuticals PLC shares had fallen by 28.6% this
quarter and gained 38.9% so far this year.
    * The company reported a quarterly loss of $14.45 million.
    * Wall Street's median 12-month price target for RVL
Pharmaceuticals PLC is $4.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
10 at 11:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.16          -0.16          Met
 Jun. 30 2022      -0.21          -0.14          Beat
 Mar. 31 2022      -0.17          -0.25          Missed
 Dec. 31 2021      -0.27          -0.30          Missed